JNK Inhibition Modulates the Cytoskeleton, Hypoxia, and Neurogenesis on the Protein Level in Glioblastoma Cells and
Can Kose1, Serap Uslu, Duygu Calik-Kocaturk
1Health Sciences University, Izmir Tepecik Education and Research Hospital, Department of IVF Unit Izmir, Turkey.
Aim:
To evaluate the effects of c-Jun N-terminal kinase (JNK) inhibition and signal blocking on hypoxia (hypoxia-inducible factor 1-alpha (HIF-1α)), differentiation and neurogenesis (bone morphogenetic protein (BMP4)), and the cytoskeleton (F-actin) in glioblastoma multiforme cells (GBMCs).
Material And Methods:
We evaluated the differences between GBMCs and astrocytes in terms of the abovementioned parameters and assessed them with the aim of studying human GBMCs (U-87 MG) and astrocytes (SVG p12). The cells were exposed to different doses of the JNK inhibitor, SP600125, for 24, 48, and 72 hours. HIF-1α, BMP4, and F-actin expressions were evaluated using immunofluorescence image analysis.
Results:
The half-maximal inhibitory concentration value for SP600125 was determined to be 10 μM at 24 hours of exposure. After SP600125 administration, elevated levels of HIF-1α and BMP4 were detected in GBMCs and astrocytes. F-actin level only increased in GBMCs after SP600125 administration.
Conclusion:
JNKs are important for cell proliferation, differentiation, survival, and death; thus, research on JNKs has become important for the treatment of many human diseases, especially brain tumors, Parkinson's disease, and Alzheimer's disease. The results of this study involving immunofluorescence techniques should be investigated and supported by studies that involve comprehensive molecular techniques.
Insights
Inhibiting c-Jun N-terminal kinase (JNK) with SP600125 increased hypoxia-inducible factor 1-alpha (HIF-1α) and bone morphogenetic protein 4 (BMP4) in glioblastoma cells. F-actin levels also rose in these cancer cells.
Area of Science:
- Neuroscience
- Molecular Biology
- Cancer Research
Background:
- Glioblastoma multiforme cells (GBMCs) exhibit unique cellular characteristics compared to normal astrocytes.
- c-Jun N-terminal kinases (JNKs) play a crucial role in cellular processes including proliferation, differentiation, survival, and apoptosis.
- Dysregulation of JNK signaling is implicated in various neurological diseases and cancers.
Purpose of the Study:
- To investigate the impact of JNK inhibition on hypoxia (HIF-1α), differentiation (BMP4), and cytoskeletal dynamics (F-actin) in glioblastoma cells.
- To compare the cellular responses of glioblastoma cells (U-87 MG) and astrocytes (SVG p12) to JNK inhibition.
Main Methods:
- Human glioblastoma cells (U-87 MG) and astrocytes (SVG p12) were treated with varying doses of the JNK inhibitor SP600125 for 24, 48, and 72 hours.
- Immunofluorescence imaging analysis was employed to quantify the expression levels of HIF-1α, BMP4, and F-actin.
- The half-maximal inhibitory concentration (IC50) of SP600125 was determined.
Main Results:
- The IC50 for SP600125 was found to be 10 μM at 24 hours.
- SP600125 treatment led to increased expression of HIF-1α and BMP4 in both glioblastoma cells and astrocytes.
- An elevation in F-actin levels was specifically observed in glioblastoma cells following SP600125 administration.
Conclusions:
- JNK signaling is a critical target for therapeutic interventions in brain tumors and other neurological disorders.
- JNK inhibition influences key cellular pathways involved in glioblastoma progression, including hypoxia and differentiation.
- Further investigation using comprehensive molecular techniques is warranted to validate these immunofluorescence findings.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
02:34Inhibition of Cdk Activity